Eli Lilly and Company $LLY Shares Sold by FUKOKU MUTUAL LIFE INSURANCE Co

FUKOKU MUTUAL LIFE INSURANCE Co cut its stake in Eli Lilly and Company (NYSE:LLY) by 32.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,309 shares of the company’s stock after selling 1,591 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Eli Lilly and Company were worth $2,525,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. OneAscent Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 32.0% in the 2nd quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock valued at $280,000 after acquiring an additional 87 shares during the period. Sequoia Financial Advisors LLC raised its position in Eli Lilly and Company by 19.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after purchasing an additional 22,410 shares during the last quarter. Finally, Schnieders Capital Management LLC. boosted its stake in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6%

Shares of NYSE LLY opened at $1,022.16 on Friday. The stock has a market capitalization of $964.26 billion, a price-to-earnings ratio of 44.54, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a 50-day moving average price of $1,053.57 and a 200 day moving average price of $925.14. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the business posted $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. CICC Research lifted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Morgan Stanley boosted their target price on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Argus increased their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Bank of America lowered their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Finally, Guggenheim upped their price objective on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,229.59.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: RBC Capital initiated coverage of LLY with an Outperform rating and $1,250 price target, citing Lilly’s obesity franchise as likely to dominate through 2030 — a vote of confidence that supports multiple‑year growth expectations. RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market
• Positive Sentiment: Detailed ACHIEVE‑3/Phase 3 results show oral orforglipron outperformed oral semaglutide on A1C and weight loss; Lilly has submitted filings in 40+ countries and is eyeing potential U.S. action for obesity in Q2 — this readout is the primary near‑term catalyst for revenue upside. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss
• Positive Sentiment: Local permits approved for a $77M expansion of Lilly’s Concord, NC manufacturing campus — a capacity investment that supports expected higher demand for GLP‑1 products and reduces execution risk from supply constraints. Eli Lilly plans $77M expansion of manufacturing campus in Concord
• Positive Sentiment: High‑profile endorsements and analyst upgrades — including Jim Cramer recommending Lilly over Novo and Guggenheim nudging its price target higher — are pushing investor sentiment toward Lilly as the GLP‑1 sector consolidates. Jim Cramer Recommends Eli Lilly over Novo Nordisk Guggenheim adjusts price target on Eli Lilly
• Neutral Sentiment: BofA and other brokers argue Novo Nordisk’s recent GLP‑1 list‑price moves shouldn’t materially dent Lilly’s U.S. franchise, tempering fears of a price war — this helps explain resilient analyst views despite industry noise. Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact
• Neutral Sentiment: Reuters and other outlets published additional safety/side‑effect details from the orforglipron diabetes trial — important for regulatory review but not showing any immediate red flags that would derail approval plans. Eli Lilly reports additional data on weight-loss pill from diabetes trial
• Negative Sentiment: Industry pricing pressure from Novo’s recent GLP‑1 list‑price cuts remains a potential headwind for gross‑to‑net and pricing dynamics; if rivals deepen price competition, margin expansion could be constrained over time. Eli Lilly stock down as Novo cuts GLP-1 prices

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.